tlog_Ex 10-1


		
			Exhibit 10.1
		

		
			 
		

		
			EXCHANGE AGREEMENT
		

		
			 
		

		
			EXCHANGE AGREEMENT (this “Agreement”), dated as of March 3, 2015, by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation, with offices located at 343 Phoenixville Pike, Malvern, PA 19355 (the “Company”), and the investor that is a signatory to this Agreement (the “Investor”).
		

		
			 
		

		
			WHEREAS, on  June 23, 2014, the Company issued certain 8.00% Convertible Senior Notes due 2019 (the “Notes”) to certain investors, which Notes are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in accordance with that certain indenture, dated June 23, 2014, by and between the Company and U.S. Bank National Association, as trustee (the “Indenture”).
		

		
			 
		

		
			WHEREAS,  the Investor currently beneficially owns and wishes to exchange such aggregate principal amount of Notes as set forth below the Investor’s name on its signature page attached hereto (the “Investor Notes”).
		

		
			 
		

		
			WHEREAS, the Company and the Investor desire to enter into this Agreement, pursuant to which, among other things, the Investor shall exchange the Investor Notes plus all accrued but unpaid interest through the date of the Exchange (as defined below), for such number of shares of Common Stock as set forth below the Investor’s name on its signature page attached hereto (the “Exchange Shares”) in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”).
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Company and the Investor hereby agree as follows:
		

		
			 
		

		
			1.EXCHANGE OF INVESTOR NOTES.
		

		
			 
		

		
			(a)On the Closing Date (as defined below), the Investor shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act, exchange the Investor Notes for the Exchange Shares, without the payment of any additional consideration (the “Exchange”), as follows:
		

		
			 
		

		
			(i)In exchange for the Investor Notes, on the Closing Date, the Company shall (A) cause American Stock Transfer & Trust Company LLC (“Transfer Agent”) to credit the Exchange Shares to the Investor’s or its designee’s account in accordance with the instructions set forth below the Investor’s name on its signature page attached hereto on the books and records of the Company kept by the Transfer Agent, and (B) pay to Investor the cash amount of $825,001.08 to the bank account designated by the Investor in writing to the Company prior to the Closing Date.
		

		
			 
		

		
			(ii)The Investor shall deliver or cause to be delivered to the Company (or its designee) for cancellation the Investor Notes through the facilities of The Depository Trust Company.
		


		

		

		 

 

		(iii)Promptly following the receipt of the Investor Notes, the Company shall surrender such Investor Notes to U.S. Bank National Association for cancellation in accordance with the provisions of the Indenture.
		

		
			 
		

		
			(iv)The Company and the Investor shall execute and/or deliver such other documents and agreements as are customary and reasonably necessary to effectuate the Exchange.
		

		
			 
		

		
			(b)The consummation of the Exchange and other transactions contemplated hereunder shall take place as soon as possible following the date hereof on a date mutually agreed to by the parties following completion of all formalities required with the Transfer Agent, Trustee and Depository Trust Company for the Exchange and confirmation of the listing of the Exchange Shares on the NASDAQ.  Such date shall be referred to herein as the “Closing Date”.
		

		
			 
		

		
			2.WAIVER.  From and after the consummation of the Exchange and receipt of the Exchange Shares hereunder, the Investor hereby waives its right to receive the payment of principal or interest under the Investor Notes and any and all rights, title and interests under the Investor Notes and the Indenture.
		

		
			 
		

		
			3.REPRESENTATIONS AND WARRANTIES
		

		
			 
		

		
			(a)Investor Representations and Warranties.  The Investor hereby represents and warrants to the Company that, as of the date hereof and as of the Closing Date:
		

		
			 
		

		
			(i)The Investor has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement by the Investor and the consummation by the Investor of the transactions contemplated hereby have been duly and validly authorized by its board of directors or other governing body, and no other proceedings on its part are necessary to authorize this Agreement or to consummate such transactions.  This Agreement has been duly and validly executed and delivered by the Investor and, assuming due authorization, execution and delivery by the other parties hereto, constitutes its legal, valid and binding obligation, enforceable against such Investor in accordance with its terms, except to the extent enforceability may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting creditors’ rights generally or by general principles governing the availability of equitable remedies.
		

		
			 
		

		
			(ii)The execution and delivery of this Agreement by the Investor does not, and the performance of this Agreement by the Investor shall not, (A) conflict with or violate its organizational documents, (B) conflict with or violate any agreement, arrangement, law, rule, regulation, order, judgment or decree to which it is a party or by which it is (or the Investor Notes held of record or beneficially owned by it are) bound or affected or (C) result in any breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a lien or encumbrance on any of the Investor Notes held of record or beneficially owned by the Investor pursuant to any note, bond,
		

		 


		

			-2-

		


		

			 

		




 

		
		

		
			mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which it is a party or by which it (or the Investor Notes held of record or beneficially owned by it) is bound or affected, except, in the case of clauses (B) and (C) of this Section 3(a)(ii), for any such conflicts, violations, breaches, defaults or other occurrences which would not prevent or delay the performance by the Investor of its obligations under this Agreement.
		

		
			 
		

		
			(iii)The execution and delivery of this Agreement by the Investor does not, and the performance of this Agreement by the Investor shall not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental entity except for applicable requirements, if any, of the Exchange Act of 1934, as amended (the “Exchange Act”) and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by the Investor of its obligations under this Agreement.
		

		
			 
		

		
			(iv)The Investor is beneficial owner of the Investor Notes and will transfer and deliver to the Company at the closing of the transactions contemplated hereunder valid title to the Investor Notes, free and clear of all security interests, liens, claims, pledges, options, rights of first refusal, preemptive or similar rights, agreements, limitations on the Investor’s voting rights, charges and other encumbrances of any nature whatsoever.
		

		
			 
		

		
			(v)The Investor is agreeing to exchange its Investor Notes and shall receive the Exchange Shares under this Agreement and pursuant to the Exchange for its own account solely for the purpose of investment and not with a view to, or for offer or sale in connection with, any distribution of the Exchange Shares in violation of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”).  The Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Exchange Shares and is able to bear the economic risk of such investment.
		

		
			 
		

		
			(vi)The Investor is a qualified institutional buyer as defined in Rule 144A under the Securities Act or an accredited investor as defined in Rule 501(a) of the Securities Act.
		

		
			 
		

		
			(b)Company Representations and Warranties.  The Company hereby represents and warrants to the Investor that, as of the date hereof and as of the Closing Date:
		

		
			 
		

		
			(i)The Company has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by its board of directors or other governing body, and no other proceedings on its part are necessary to authorize this Agreement or to consummate such transactions.  This Agreement has been duly and validly executed and delivered by the Company and, assuming due authorization, execution and delivery by the other parties hereto, constitutes its legal, valid and binding obligation, enforceable against the Company in accordance with its terms, except to the extent enforceability may be limited by bankruptcy, insolvency, moratorium
		

		 


		

			-3-

		


		

			 

		




 

		
		

		
			or other similar laws affecting creditors’ rights generally or by general principles governing the availability of equitable remedies.
		

		
			 
		

		
			(ii)the Exchange and the issuance of the Exchange Shares is duly authorized and upon issuance in accordance with the terms of this Agreement, the Exchange Shares will be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof.
		

		
			 
		

		
			(iii)The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company shall not, (A) conflict with or violate its organizational documents, (B) conflict with or violate any agreement, arrangement, law, rule, regulation, order, judgment or decree to which it is a party or by which it is bound or affected, except, in the case of clause (B) of this Section 3(b)(iii), for any such conflicts, violations, breaches, defaults or other occurrences which would not prevent or delay the performance by the Company of its obligations under this Agreement.
		

		
			 
		

		
			(iv)The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company shall not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental entity except for applicable requirements, if any, of the Exchange Act and the listing of the Exchange Shares on the NASDAQ, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by the Company of its obligations under this Agreement.
		

		
			 
		

		
			4.COVENANTS.
		

		
			 
		

		
			(a)Section 3(a)(9).  The Company represents that the exchange of the Investor Notes for the Exchange Shares is being made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act and agrees not to take any position contrary to this Section 4(a).
		

		
			 
		

		
			(b)No Transfer.  Prior to the Closing Date, the Investor agrees to not dispose or attempt to dispose, directly or indirectly, by operation of law or otherwise, voluntarily or involuntarily, of any Investor Notes, or any right, power, or interest therein, including through any sale, gift, pledge, encumbrance, or creation of a security interest in any Investor Note.
		

		
			 
		

		
			(c)Investment Considerations.  The Investor understands the Exchange Shares have not been and will not be registered under the Securities Act or the securities laws of any state of the United States and that the sale contemplated hereby is being made in reliance on an exemption from such registration pursuant to Section 3(a)(9) of the Securities Act and, as such, the Exchange Shares will be subject to any transfer restrictions applicable to the Investor Notes.  The Investor has not acted on behalf of the Company and has received no commission or remuneration from the Company.  The Investor was not solicited by anyone on behalf of the Company to enter into this transaction, and it has not solicited any other investor of the Company’s Notes to participate in a similar transaction.  The Exchange Shares to be received by the Investor shall not contain a restrictive legend.
		

		 


		

			-4-

		


		

			 

		




 

		
		

		
			(d)Post-Closing Disclosure Requirement of the Company.   No later than the close of business on the business day after the date of this Agreement, the Company shall publicly disclose the transactions contemplated by this Agreement pursuant to a Form 8-K filing with the United States Securities and Exchange Commission.
		

		
			 
		

		
			5.MISCELLANEOUS.
		

		
			 
		

		
			(a)Permission to Disclose.  The Investor hereby agrees and consents to the disclosure by the Company of this Agreement in connection with the Exchange or as otherwise required by law (including on a Form 8-K).
		

		
			 
		

		
			(b)Specific Performance.  The parties hereto agree that irreparable damage would occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity.
		

		
			 
		

		
			(c)Entire Agreement.  This Agreement constitutes the entire agreement between the Company and the Investor with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, between the Company and the Investor with respect to the subject matter hereof.
		

		
			 
		

		
			(d)Amendment.  This Agreement may not be amended and no other actions may be taken under this Agreement except by an instrument in writing signed by the Company and the Investor.
		

		
			 
		

		
			(e)Severability.  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of this Agreement is not affected in any manner materially adverse to any party.  Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereby shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable law in a mutually acceptable manner in order that the terms of this Agreement remain as originally contemplated.
		

		
			 
		

		
			(f)Notices.  All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given or made and shall be effective upon receipt, if delivered personally, upon receipt of a transmission confirmation if sent by facsimile (with a confirming copy sent by overnight courier) and on the next business day if sent by Federal Express, United Parcel Service, Express Mail or other reputable overnight courier to the parties at the following addresses (or at such other address for a party as shall be specified by notice):
		

		
			 
		

		
			If to the Investor, to the address specified on the signature page attached hereto.  With a copy to:
		

		 


		

			-5-

		


		

			 

		




 

		
		

		
			Geode Capital Master Fund Ltd. — CBARB Segregated Accountc/o Geode Capital Management, LLC
		

		
			One Post Office Square, 20th floor
		

		
			Boston, MA 02109
		

		
			Telephone: (617) 563-3499
		

		
			Fax: (617) 385-0701
		

		
			Attention: Chief Operating Officer
		

		
			 
		

		
			If to the Company, to:
		

		
			 
		

		
			TetraLogic Pharmaceuticals Corporation
		

		
			343 Phoenixville Pike
		

		
			Malvern, PA 19355
		

		
			Telephone: (610) 889-9900
		

		
			Fax: (610) 889-9994
		

		
			Attention: General Counsel
		

		
			 
		

		
			with a copy to:
		

		
			 
		

		
			Pepper Hamilton LLP
		

		
			400 Berwyn Park
		

		
			899 Cassatt Road
		

		
			Berwyn, PA 19312-1183
		

		
			Telephone: (610) 640-7825
		

		
			Fax: (610) 640-7835
		

		
			Attention: Jeffrey P. Libson, Esq.
		

		
			 
		

		
			(g)Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed entirely within such state.
		

		
			 
		

		
			(h)MUTUAL WAIVER OF JURY TRIAL.  BECAUSE DISPUTES ARISING IN CONNECTION WITH COMPLEX TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE AND FEDERAL LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS.  THEREFORE, EACH PARTY TO THIS AGREEMENT HEREBY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES HERETO, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE, ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS AGREEMENT AND/OR THE TRANSACTIONS CONTEMPLATED HEREBY.
		

		
			 
		

		
			(i)Consent to Jurisdiction.  Each party (i) hereby irrevocably submits to the exclusive jurisdiction of the United States courts and New York State courts sitting in Manhattan, New York City, State of New York, for the purposes of any suit, action or
		

		 


		

			-6-

		


		

			 

		




 

		
		

		
			proceeding arising out of or related to this Agreement and (ii) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such courts, that the suit action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  Each party consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing in this Section 5(i) shall affect or limit any right to serve process in any other manner permitted by law.
		

		
			 
		

		
			(j)Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which, when taken together, shall constitute one and the same instrument.
		

		
			 
		

		
			(k)Fees and Expenses.  Except as otherwise provided in this Agreement, each party shall bear its own expenses, including the fees and expenses of accountants, financial or other advisors or representatives engaged by it, incurred in connection with this Agreement and the transactions contemplated hereby.
		

		
			 
		

		
			(l)Survival of Representations, Warranties and Covenants.  The representations and warranties contained in or made pursuant to this Agreement shall survive the closing of the transactions contemplated hereunder without limitation.
		

		
			 
		

		
			(m)Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors or assigns.
		

		
			 
		

		
			[Signature Pages Follow]
		

		

		

		 


		

			-7-

		


		

			 

		




 

		
		

		
			The Investor and the Company have caused their respective signature pages to this Agreement to be duly executed as of the date first written above.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						COMPANY

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						TETRALOGIC PHARMACEUTICALS CORPORATION

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Pete A. Meyers

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Chief Financial Officer and Treasurer

				



		
			 
		

		

		

		 


		

			-8-

		


		

			 

		




 

		
		

		
			The Investor and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						INVESTOR

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						GEODE CAPITAL MASTER FUND LTD., solely on behalf of CBARB SEGREGATED ACCOUNT

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						GEODE CAPITAL MANAGEMENT LP,

				
	
					
						 

					
					
						 

					
					
						 

					
					
						as Investment Manager

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Name: Jeffrey S. Miller

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Title: Chief Operating Officer

				
	
					
						 

					
					
						 

					
					
						 

					
					
						One Post Office Square, 20th floor

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Boston, MA 02109

				
	
					
						 

					
					
						 

					
					
						Telephone: (617) 563-3499

				
	
					
						 

					
					
						 

					
					
						Fax: (617) 385-0701

				



		
			 
		

		
			Aggregate Principal Amount of Investor Notes to be Exchanged: $2,750,000
		

		
			 
		

		
			Number of Exchange Shares: 407,830
		

		
			 
		

		
			Transfer Agent/Broker Information:
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				



		
			 
		

		 


		

			-9-